Related Experiment Video
Updated: Dec 28, 2025
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Predisposing factors for late mortality in heart transplant patients
Emyal Alyaydin1, Henryk Welp2, Holger Reinecke1
1Department of Cardiology I, University of Muenster, Germany.
Insights
Identifying risk factors for late mortality after heart transplantation is crucial. Key predictors include low CD4+ cell counts, inflammation, past rejections, early cardiac allograft vasculopathy, and not using beta-blockers.
Area of Science:
- Cardiology
- Transplantation Immunology
- Nephrology
Background:
- Growing prevalence of end-stage heart failure and organ donor shortages necessitate optimal long-term care for heart transplant recipients.
- Understanding risk factors for late mortality is essential for improving patient outcomes post-transplantation.
Purpose of the Study:
- To identify predisposing factors associated with late mortality in patients who have undergone heart transplantation.
Main Methods:
- Retrospective analysis of clinical, laboratory, immune monitoring, and examination data from long-term heart transplant patients.
- Patients were divided into survivors and non-survivors for comparative analysis of mortality risk factors.
Main Results:
- Non-survivors exhibited more severe renal insufficiency, anemia, poorer functional status, and received hearts from more obese donors.
- Independent risk factors for mortality included low CD4+ cell percentage (<42%), elevated C-reactive protein (≥0.5 mg/dL), history of rejection, early cardiac allograft vasculopathy (<5 years), and non-use of beta-blockers.
Conclusions:
- Low CD4+ cell percentages, persistent inflammation, significant organ rejections, and early cardiac allograft vasculopathy are critical risk factors for long-term mortality.
- The absence of beta-blocker use is also identified as a significant risk factor contributing to higher mortality rates in heart transplant survivors.
Background:
Because of the growing prevalence of terminal heart failure on the one hand and organ shortage on the other hand, an optimal care of heart transplant recipients based on the knowledge of potential risk factors not only early, but also in a long-term course after heart transplantation is of great importance. Therefore, the aim of the present study was to identify predisposing factors for late mortality in this patient collective.
Methods:
Data from long-term heart transplant patients collected during follow-up visits in the current center were retrospectively analyzed. Clinical, laboratory, including immune monitoring and apparative examination results were studied with regard to all-cause mortality.
Results:
One hundred and seventy-two patients after heart transplantation (mean: 13.2 ± 6.4 years) were divided into two groups: survivors (n = 133) and non-survivors (n = 39). In comparison with survivors, non-survivors were characterized by significantly more pronounced renal insufficiency with more frequent dialysis, anemia and worse functional status. Additionally, non-survivors obtained hearts from relevantly more obese donors. In a multivariate Cox regression analysis the following parameters were shown to be independent risk factors for increased mortality: CD4 percentage < 42%, C-reactive protein ≥ 0.5 mg/dL, presence of rejections requiring therapies in the past, onset of cardiac allograft vasculopathy < 5 years following heart transplantation and no use of beta-blockers.
Conclusions:
Low CD4+ cell percentages, sustained inflammation, relevant organ rejections, early onset of transplant vasculopathy and no use of beta-blockers are risk factors for higher mortality in a long-term follow-up after heart transplantation.
More Related Videos
07:08A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
12:40A Modified Murine Heterotopic Heart Transplant Protocol Matching Contemporary Standards of Aseptic Technique, Anesthesia, and Analgesia
Published on: September 28, 2022
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:27Heart Failure I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:29Cardiomyopathy V: Interprofessional Care